Numbers needed to treat (lives!) and numbers needed to save (money)

EuroIntervention

Volumn 9, Issue 2, 2013, Pages 175-177

  Ribichini, Flavio ^a   Taggart, David ^b   Vassanelli, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPLASTY; AORTA STENOSIS; ARTERY GRAFT; CARDIOLOGIST; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEALTH ECONOMICS; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LIFE SUSTAINING TREATMENT; MINIMALLY INVASIVE PROCEDURE; PATIENT CARE; PRIMARY PREVENTION; QUALITY OF LIFE; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURGEON; TRANSCATHETER AORTIC VALVE IMPLANTATION; VALVULAR HEART DISEASE; CARDIOLOGY; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; HEALTH CARE COST; HEART CATHETERIZATION; HEART VALVE DISEASES; HEART VALVE REPLACEMENT; MORTALITY; NUMBERS NEEDED TO TREAT; STATISTICAL MODEL; TREATMENT OUTCOME;

CARDIAC CATHETERIZATION; CARDIOLOGY; CARDIOVASCULAR DISEASES; COST SAVINGS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MODELS, ECONOMIC; NUMBERS NEEDED TO TREAT; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 84880000228     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9I2A28     Document Type: Editorial

References (12)

1. Ribichini F, Ferrero V, Wijns W. Reperfusion treatment of ST-elevation acute myocardial infarction. Prog Cardiovasc Dis. 2004;47:131-57. (Pubitemid 39600947)
2. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med. 2003;138:445-52.
3. Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12:1564-70.
4. Tung R, Swerdlow CD. Refining patient selection for primary prevention implantable cardioverter-defibrillator therapy: reeling in a net cast too widely. Circulation. 2008;120:825-7.
5. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501-55.
6. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S; Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27:1979-2030.
7. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-607.
8. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187-98.
9. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451-96.
10. Van Brabandt H, Neyt M, Hulstaert F. Transcatheter aortic valve implantation (TAVI): risky and costly. BMJ. 2012;345:e4710.
11. Neyt M, Van Brabandt H. Cost-effectiveness of transcatheter aortic valve replacement: over-optimistic study results and a call for publication of complete trial results. Heart. 2012;98:1031-3.
12. Reynolds MR, Magnuson EA, Lei Y, Wang K, Vilain K, Li H, Walczak J, Pinto DS, Thourani VH, Svensson LG, Mack MJ, Miller DC, Satler LE, Bavaria J, Smith CR, Leon MB, Cohen DJ; PARTNER Investigators. Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). J Am Coll Cardiol. 2012;60:2683-92.